Davis-based Marrone Bio Innovations has raised $25.4 million in series C funding. New investors are Syngenta Ventures, Mitsui Global Investment and a family investment trust. The existing investors include Stuart Mill Venture Partners, Contrarian Group and Calvert Social Ventures, as well as several individual investors. The venture capital-backed firm is using the funding for expanding global sales of Regalia Biofungicide, launch of Zequanox and other pipeline products.
Click here for the release from Marrone Bio Innovations.